Novotech is internationally recognized in the industry as a leading regional full-service CRO. Headquartered in Australia and focused exclusively on the Asia Pacific.Novotech is one of the few organizations in the industry that have secured accreditation with the International Standards Organisation (ISO). As a result of our continued successful external audits, Novotech is proud to be a fully Quality Endorsed Company compliant to the ISO9001:2000 standard.
|Type||Public / Private|
With the increasing pace of globalization in drug development, Novotech's expertise in the vibrant and fast-growing Asian region has been instrumental in the success of hundreds of clinical trials from Australia to India.
Both in Australia and internationally, Novotech boasts some of the most experienced Project managers and CRAs in the industry. All Novotech associates and PMs are trained in Novotech's cloud-based Enterprise resource planning (ERP) solution for optimal resource planning and utilization across projects. This enables greater efficiency across multinational projects and high level of automation in service delivery.
Established in 1996, Novotech is Australia’s largest independent contract research organization (CRO). The Australian Head Office is situated in Sydney, with regional offices in Melbourne and Brisbane - providing easy access to the most important population centers in Australia. Supported by regional staff across the country and in New Zealand, our coverage of the Australia/New Zealand region is second to none.
With Asian services launched in 2007, Novotech’s operations provide access to the most dynamic and fast-growing clinical research hubs in the region.
In addition, we offer worldwide reach to our clients through key external partnerships and strategic alliances, with partners in the US, Canada, Europe, and China.
The combination of a relatively small, flexible contract research organization (CRO), coupled with the ability to confidently manage very large projects allows us to move a project from initial planning stage to recruitment with dramatic speed.
Top 5 Recent Tweets
|September 20, 2022||pharminews||Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference… https://t.co/RtAAuYOhkQ|
Top 5 Recent News Headlines
Novotech receives ISO 9001:2015 certification
29 June 2017, Sydney, Australia: Asia Pacific specialist CRO Novotech announced today it has received ISO 9001:2015 Quality Management System certification for its corporate headquarters in Sydney, Australia.
19 June 2017, Sydney, Australia: Asia Pacific specialist CRO Novotech announced today it has expanded its business offering to include central lab services through a preferred partnership agreement with Sonic Clinical Trials, an affiliate of international healthcare company, Sonic Healthcare.
Through this unique partnership, Novotech clients will be able to select from a wide menu of assays or biomarkers, access a trial-specific kit assembly service and use a single clinical trial-dedicated laboratory with a global reach, for priority processing of clinical trial samples.
Announcing the new partnership, Novotech CEO Dr. John Moller said “Novotech has always focused on offering flexible and cost-effective clinical trial solutions. Through our partnership with Sonic Clinical Trials, our clients will experience a seamless integration of laboratory services and clinical trial data management by Novotech. From the start to finish, our clients are supported by a team of dedicated project managers.
“Another key benefit to our clients is the fact that Sonic Clinical Trials is pre-audited and an approved Novotech vendor. This removes our clients’ need to undertake their own central lab vendor assurance – providing further savings in cost and clinical trial time.”
Sonic Clinical Trials is also a registered Research Service Provider (RSP) with AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science. “Sonic Clinical Trials’ RSP status assists our eligible international clients when accessing the Australian R&D Tax Incentive Scheme**. Research from a recent Frost and Sullivan white paper revealed that eligible companies can conduct early stage clinical trials 60% more cheaply in Australia than the USA,” explained Dr. Moller, “Novotech’s size and Asia Pacific focus allows our clients to enjoy a direct, hands-on approach to accessing some of the largest patient pools in the world but we balance this with providing global gold-standard central laboratory services and data management platforms.”